Anti-COL9A1 Polyclonal Antibody for WB and ELISA - P20849

Core Product Specifications and Parameters

Biological Background: COL9A1 Function and Localization

• COL9A1 encodes the alpha-1 chain of type IX collagen, a fibril-associated collagen with interrupted triple helices (FACIT) that is a structural component of hyaline cartilage and the vitreous of the eye.
• Type IX collagen molecules are heterotrimers consisting of α1(IX), α2(IX), and α3(IX) chains, and they associate with type II collagen fibrils, likely contributing to the integrity and organization of the extracellular matrix.
• COL9A1 undergoes alternative splicing and contains multiple domains, including collagenous and non-collagenous regions, essential for its interaction with other matrix components.
• The protein is secreted and localized to the extracellular space and matrix, where it participates in the assembly and stabilization of cartilage and vitreous structures.
• Post-translational modifications such as hydroxylation, glycosylation, and disulfide bond formation are critical for its stability and function.
• Mutations in COL9A1 are associated with skeletal dysplasias and connective tissue disorders, including Stickler syndrome (characterized by ocular, auditory, and articular abnormalities) and multiple epiphyseal dysplasia, highlighting its clinical significance.
• The protein contains a signal peptide and zinc-binding sites, and its mature form is a secreted glycoprotein.

Experimental Guidance and Technical Tips

• The immunogen used to generate this polyclonal antibody is a recombinant protein corresponding to amino acids 20–270 of human COL9A1, covering part of the N-terminal non-collagenous domain, which may provide specificity for the α1(IX) chain.
• For Western blot (WB), a band around 92 kDa is expected for full-length COL9A1 in human cartilage or vitreous samples; however, due to alternative splicing and post-translational modifications, additional bands or shifts in molecular weight may be observed.
• The antibody shows cross-reactivity with rat COL9A1, suggesting it can be used in rat models; validate in relevant tissue lysates or recombinant systems to confirm reactivity.
• For ELISA applications, consider using purified recombinant COL9A1 as a coating antigen or capture standard, and perform appropriate optimization of antibody dilution and detection conditions.
• Always include appropriate positive (cartilage extracts, recombinant protein) and negative controls to confirm specificity and minimize background.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is your dedicated partner for sourcing high-quality IVD raw materials and reagents. Whether you need validated antibody pairs, optimized monoclonal or polyclonal antibodies, bulk ancillary reagents, or support for rare target raw-material procurement, we offer a streamlined one-stop supply solution. Our COL9A1 polyclonal antibody is backed by reliable recombinant protein-based immunogen design and stringent quality control, making it suitable for research and diagnostic assay development in cartilage biology and connective tissue disorders.